More than 30 million Americans have diabetes, and nearly a quarter of them use insulin to manage their symptoms and prevent life-threatening complications. The price they have to pay for insulin is more than ten times higher than the average prices in 32 other countries combined.
Despite the buzz and catchy notion that subscription models are “Netflix for drugs,” it's hard to come up with a theoretical case that supports subscription models over traditional price negotiation between payers and manufacturers over a per-dose or per-unit price.
State and federal policymakers are considering adding state-backed public options to the individual market in an effort to expand health coverage and improve affordability. We analyzed what would happen if public options became available in U.S. health insurance exchanges.
The final State of the Union address of President Trump's four-year term may be viewed through the lens of the unprecedented circumstances surrounding the evening. But the speech touched on a range of policy challenges that will remain, regardless of how politics play out in 2020.
Most Americans, including Congress and the president, agree that prescription drug prices are too high. Policy proposals from both major parties could promise some relief. Several of them look to drug prices in other countries to help set prices in the United States.
For busy staff, August's respite from back-to-back meetings, hearing preparation, and late votes is hard-earned. The summer recess also provides an opportunity to get ahead of issues that will resurface in the fall. To that end, we have compiled recent RAND research on topics likely to top the congressional agenda come September.
A massive lawsuit filed by 44 states accuses 20 major drug makers of colluding to inflate prices on more than 100 generic drugs, including HIV, cancer, and depression treatments. If these allegations are true, then this isn't just a violation of antitrust law. It's a betrayal of the policies that created and defended the entire generic drug industry.